Skip to main content

Justin Balko Archives

Twelve at Vanderbilt are among world’s highly cited researchers

Nov. 15, 2023—Twelve current investigators at Vanderbilt University Medical Center and Vanderbilt University are on this year’s list of scientists whose papers have been cited the most frequently by other researchers.

Read more


Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Oct. 4, 2023—Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

Read more


Several from VUMC among most highly cited researchers

Nov. 17, 2022—Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

Read more


Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

Nov. 16, 2022—Researchers from from Vanderbilt-Ingram Cancer Center have identified the mechanism for the deadly heart inflammation myocarditis.

Read more


Breast cancer biomarkers of response

Jun. 16, 2022—Vanderbilt researchers have identified blood-based biomarkers associated with complete responses to neoadjuvant chemotherapy in patients with breast cancer.

Read more


Study identifies biomarker for breast cancer response to immunotherapy

Aug. 12, 2021—A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Read more


Arthritis drug may treat immunotherapy-related heart complication

Dec. 22, 2020—by Tom Wilemon A drug typically prescribed for rheumatoid arthritis may also be effective in treating a rare but potentially deadly heart complication some cancer patients experience after taking immunotherapies, according to a study published in Cancer Discovery and co-led by investigators at Vanderbilt University Medical Center. The researchers demonstrated that the drug abatacept reduced...

Read more


Health workers sought for hydroxychloroquine study

Apr. 23, 2020—Health care workers at Vanderbilt University Medical Center at high risk of exposure to COVID-19 can participate in a randomized, controlled clinical trial testing the effectiveness of the drug hydroxychloroquine (HCQ) in preventing infection.

Read more


Balko lands Mary Kay Foundation grant for breast cancer research

Dec. 5, 2019—Vanderbilt-Ingram Cancer Center's Justin Balko, PharmD, PhD, has received a $100,000 research grant from the Mary Kay Foundation.

Read more


Encephalitis identified as rare toxicity of immunotherapy treatment

Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Read more


Cancer Center investigators awarded Komen grants

Oct. 11, 2018—Four Vanderbilt-Ingram Cancer Center (VICC) investigators have received financial support from Susan G. Komen for breast cancer research.

Read more


Study seeks to boost breast tumor immune response

Feb. 8, 2018—Immunotherapy, which harnesses the power of the immune system, is one of the most promising forms of cancer therapy and has been shown to work well against some types of cancer.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more